/Therapeutic Targeting Of Tumor Escape By Car-mediated Trogocytosis
Abstract

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.

Full Text

What is claimed is:

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.
Timeline
Filed
05/01/2026
Published
08/20/2026
Granted
Not Available
IPC Codes(9)
A61K 40/42:Cancer antigens
A61K 40/11:T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
A61K 40/31:Chimeric antigen receptors [CAR]